SEC Comment Letter 0000000000-23-009015 to Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522) (NMRA)
Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522)
Date: Aug. 17, 2023 · CIK: 0001885522 · Accession: 0000000000-23-009015
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo August 17, 2023 Henry Gosebruch Chief Executive Officer Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472 Re:Neumora Therapeutics, Inc. Amendment No. 9 to Draft Registration Statement on Form S-1 Submitted August 9, 2023 CIK No. 0001885522 Dear Henry Gosebruch: We have reviewed your amended draft registration statement and have the following comment. In our comment we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to this comment and your amended draft registration statement or filed registration statement, we may have additional comments. Amendment No. 9 to Draft Registration Statement on Form S-1 submitted August 9, 2023 Prospectus Summary Overview, page 1 1.We note your statements throughout the prospectus that several of your programs target novel mechanisms of actions that "have shown preclinical and clinical validation" by Neumora and other leading biopharmaceutical companies. Please revise your disclosure to explain what you mean by "validation" and provide support for each statement. Please also ensure that this disclosure does not imply that approval by the FDA or similar regulatory bodies is assured, as such determination is not within the control of the company.
FirstName LastNameHenry Gosebruch Comapany NameNeumora Therapeutics, Inc. August 17, 2023 Page 2 FirstName LastName Henry Gosebruch Neumora Therapeutics, Inc. August 17, 2023 Page 2 You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Daniel Crawford at 202-551-7767 or Laura Crotty at 202-551-7614 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phillip Stoup, Esq.
Show Raw Text
United States securities and exchange commission logo
August 17, 2023
Henry Gosebruch
Chief Executive Officer
Neumora Therapeutics, Inc.
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
Re:Neumora Therapeutics, Inc.
Amendment No. 9 to Draft Registration Statement on Form S-1
Submitted August 9, 2023
CIK No. 0001885522
Dear Henry Gosebruch:
We have reviewed your amended draft registration statement and have the following
comment. In our comment we may ask you to provide us with information so we may better
understand your disclosure.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe our comment applies to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this comment and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Amendment No. 9 to Draft Registration Statement on Form S-1 submitted August 9, 2023
Prospectus Summary
Overview, page 1
1.We note your statements throughout the prospectus that several of your programs target
novel mechanisms of actions that "have shown preclinical and clinical validation" by
Neumora and other leading biopharmaceutical companies. Please revise your disclosure to
explain what you mean by "validation" and provide support for each statement. Please
also ensure that this disclosure does not imply that approval by the FDA or similar
regulatory bodies is assured, as such determination is not within the control of the
company.
FirstName LastNameHenry Gosebruch
Comapany NameNeumora Therapeutics, Inc.
August 17, 2023 Page 2
FirstName LastName
Henry Gosebruch
Neumora Therapeutics, Inc.
August 17, 2023
Page 2
You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738 if you have
questions regarding comments on the financial statements and related matters. Please contact
Daniel Crawford at 202-551-7767 or Laura Crotty at 202-551-7614 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Phillip Stoup, Esq.